GlassScriptPhysician profile
Allison A Tillman
NPI 1508471459
$9,018.60
in general payments reported to CMS, 2019-2025
51 companies · $2,279 in 2025
The $2,279 reported for 2025 was more than what 95% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,708 · 2022: $1,463 · 2023: $1,102 · 2024: $1,467 · 2025: $2,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,834 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,834.29 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,778.40 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $924.57 | 2021 | |
| Lilly USA, LLC | $756.56 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $616.56 | 2022-2025 | Repatha, Tepezza, Otezla |
| Indivior INC. | $560.53 | 2021-2024 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $494.27 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $410.54 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Braeburn INC. | $380.90 | 2023-2024 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $309.92 | 2022-2025 | |
| Cequr Corporation | $297.13 | 2025 | Cequr Simplicity |
| Teva Pharmaceuticals USA, INC. | $263.74 | 2021-2022 | |
| Pfizer INC. | $252.24 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $189.54 | 2025 | |
| Glaxosmithkline, LLC. | $170.26 | 2021-2024 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $91.17 | 2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Tillman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.